80 results about "Mitochondrion membrane" patented technology

The invention discloses a nasal delivery multistage targeting bionic nano drug delivery system as well as a preparation method and application of the nasal delivery multistage targeting bionic nano drug delivery system. According to the drug delivery system, a black phosphorus nanosheet with an active oxygen scavenging effect is used as an inner core carrier, a neuroprotective agent fingolimod hydrochloride FTY720 and polydimethyldiguanide PolyMet are loaded, and a microcolloid cell membrane and a mitochondrial membrane are modified on the surface of the preparation; the nano drug delivery system is applied to treatment of cerebral arterial thrombosis reperfusion injury, can overcome the blood brain barrier, can quickly enter the brain through nasal administration, realizes efficient delivery of drugs, remarkably reduces the cerebral infarction area, reduces the brain inflammation level, protects nerve cells, greatly relieves cerebral arterial thrombosis reperfusion injury, and has application prospects.

The invention relates to the technical field of biological medicines, and particularly discloses application of betaine in preparation of a medicine for preventing or treating sepsis myocardial injury. Betaine (BET) provided by the invention can be used for effectively relieving cytokine storm caused by sepsis injury and inhibiting reduction of core body temperature of a mouse; the abnormal blood routine and blood biochemical indexes are improved. In addition, betaine can reduce generation of active oxygen in myocardial cells of the HL-1 mouse and improve mitochondrial membrane potential imbalance of the myocardial cells of the HL-1 mouse. The chemical structural formula of the betaine is shown in the specification.

The invention discloses a preparation method of DRP1 engineered mitochondrial derived vesicles and application of the DRP1 engineered mitochondrial derived vesicles in cell aging resistance. The method comprises the following steps: firstly, constructing a lentiviral vector of an overexpressed DRP1 gene, and transfecting cells to obtain a cell strain of the stable overexpressed DRP1 gene; and culturing the cell strain, collecting a culture solution, and separating and extracting the mitochondrial derived vesicles to obtain the DRP1 engineered mitochondrial derived vesicles DRP1-MDVs rich in mtDNA. The DRP1-MDVs is used for treating senescent cells, the DRP1-MDVs is successfully internalized into senescent cells, the ROS level can be effectively reduced, the mitochondrial mtDNA and ATP content can be improved, the mtDNA mutation rate can be reduced, the mitochondrial membrane potential and the mitochondrial network structure can be recovered, and finally the expression of senescence-related proteins P16 and P21 can be reduced. The obvious mitochondrial function repairing potential and the cell aging improving effect are shown.

This invention relates to the field of cosmetic compositions, and more specifically to a synergistic anti-aging composition involving energy metabolism and autophagy, its preparation method, and its application. The composition comprises sea buckthorn fruit extract, trehalose, and a cosmetically acceptable polyol carrier. This invention pioneers a betaine-trehalose-NADES extraction system, achieving low-temperature, high-efficiency extraction while preserving the heat-sensitive active ingredients of sea buckthorn. Trehalose possesses both extraction and autophagy activation effects. A selective separation strategy achieves a balance between efficacy, compliance, and process simplicity. The green, circular process reduces costs and is environmentally friendly. Through the synergistic effect of sea buckthorn fruit extract and trehalose, the composition enhances mitochondrial membrane potential, increases ATP production, inhibits excessive activation of the mTOR pathway, and promotes LC3-II conversion, thus synergistically combating skin aging from multiple targets including cellular energy metabolism, signaling pathways, and autophagy.

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The invention discloses a protein complex for protecting mitochondria from being damaged, a pharmaceutical composition and application. According to the application, the influence of nitrate on mitochondrial injury in in-vivo radiation-induced salivary gland injury and in-vitro human salivary gland cell injury is evaluated, the action mechanism in the mitochondrial injury is further deeply explored, and a result shows that sialic acid transporter interacts with FKBP8, so that the mitochondrial injury can be inhibited, and the mitochondrial injury can be inhibited. In turn, particles are formed and anchored on the outer mitochondrial membrane, thereby maintaining membrane integrity. Therefore, the invention provides a brand new therapeutic target for preventing radiation-induced salivary gland injury and other mitochondrial membrane related diseases.

The application discloses a tumor-penetrating carrier-free nanomedicine as well as a preparation method and application thereof, and belongs to the field of nanomedicine. The carrier-free nanomedicine can significantly improve water solubility of a water-insoluble compound, has mitochondrion targeting and tumor active penetration capabilities, and under the action of a tertiary amine nitrogen oxygen group, the carrier-free nanomedicine can be mostly transported into mitochondria, which is beneficial to inducing a mitochondrion membrane potential drop and cell apoptosis. The carrier-free nanomedicine also has a good blood long-circulation effect and tumor accumulation capability in a body, and an antitumor effect is better than that of a clinical drug, and the carrier-free nanomedicine also has good biological safety. The preparation method is simple, and can be used for preparation of an antitumor drug.

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

The application discloses Bifidobacterium Pseudocatenulatum and application thereof, and the Bifidobacterium Pseudocatenulatum YSBP01CCTCC NO: M 20232067. Experiments prove that the Bifidobacterium Pseudocatenulatum can enhance the antioxidant capacity of Caenorhabditis elegans, prolong the life of the nematode, improve the activity and the reproductive capacity of the nematode, reduce fat accumulation, improve the mitochondrial membrane potential, and delay the aging of the body. The Bifidobacterium Pseudocatenulatum can also significantly inhibit the weight increase of a high-fat-diet mouse, reduce the TG level in serum of the mouse, significantly reduce the fasting blood glucose concentration, and effectively prevent and relieve obesity and type 2 diabetes.

This invention discloses a method for detecting mitochondrial membrane potential in the gills or hepatopancreas of crustaceans, belonging to the field of mitochondrial membrane potential detection technology. This invention, by addressing the structural and physiological differences between gill and hepatopancreas tissues in crustaceans, formulates differentiated incubation strategies: for gill tissue, a "live pre-equilibration-short-time staining-rapid slide preparation" method is used, strictly controlling the JC-1 incubation time to within 10 minutes to effectively avoid probe toxicity damage to mitochondria; for hepatopancreas tissue, in vivo incubation is extended to 1 hour to ensure sufficient dye penetration. Under the condition of uniformly using 2 μM JC-1 and 20 μmol / L CCCP as positive controls, this method significantly improves the tissue penetration and signal uniformity of the dye, solving problems such as uneven staining and weak signal caused by exoskeleton barriers and high lipid content, providing reliable technical support for aquatic health assessment and toxicology research.

The invention discloses a method for synergistically improving the activity of porcine oocytes through low-temperature plasma and erythritol, and belongs to the technical field of reproductive biology. The method comprises the following steps: collecting pig ovaries and separating oocytes; freezing protection is carried out by adopting a freezing liquid (DMSO: EG: FSF = 2: 2: 6) containing 0.5 mol / L erythritol, and preservation is carried out at-80 DEG C for 48 hours; and after unfreezing, treating for 30 seconds by using low-temperature plasma (6.83 kHz, 4.8 kV) to activate the cells. Experiments show that the erythritol can reduce frozen ice crystal damage, and the plasma treatment can significantly improve the cell activity after resuscitation, reduce the ROS content, increase the GSH reserve and enhance the mitochondrial membrane potential. And the survival rate of the oocytes is improved through synergism of the two. The problems that the cell activity is reduced and oxidative damage is serious in the cryopreservation process are solved, and an efficient technical scheme is provided for preservation of pig germplasm resources.

The application discloses a kind of mitochondrial quality control detection methods, the present application relates to mitochondrial quality control detection technical field, operating steps include preparation sample cell suspension, fluorescent dye labeling, cardiomyocyte separation, establish myocardial cell damaged model and detect mitochondrial membrane potential situation.This mitochondrial quality control detection method can simultaneously carry out multi-parameter, rapid quantitative analysis and sorting, measure fast, measure the multi-parameter characteristics of each cell, while carrying out cell characteristic analysis, can separate out the cell of specified characteristics, so as to further culture, cloning, observation or carry out mitochondrial fragmentation test to specific cell, establish myocardial cell damaged model using doxorubicin, the mitochondrial membrane potential situation of normal myocardial cell and damaged myocardial cell obtained by using JC-1 mitochondrial membrane potential fluorescent probe detection is verified the detection quality of this mitochondrial quality control detection method.

The invention provides a liposome for protecting mitochondrial vesicles of mesenchymal stem cells as well as a preparation method and application of the liposome, and belongs to the technical field of liposome preparation. The liposome comprises a lipid membrane and a mitochondrial protective agent located in the lipid membrane, preparation raw materials of the lipid membrane comprise DOPC, DOTAP, cholesterol and DSPE-PEG2000, and preparation raw materials of the mitochondrial protective agent comprise human serum albumin, trehalose, glutathione, tryptophan and the like. The liposome has good biocompatibility and safety, and immunogenicity and toxicity risks are reduced. After the lipidosome is fused into the mitochondrial vesicles, the structural integrity, the membrane fluidity and the functional activity of mitochondria can be effectively maintained, mitochondrial swelling and collapse are reduced, and the mitochondrial membrane potential is maintained; the liposome vesicles can be stably stored for 6-8 hours at 25 DEG C, and the short-distance transportation requirement is met. The preparation raw materials of the liposome are low in cost, the preparation method is simple and easy to implement, and the liposome is suitable for large-scale production.

The application discloses a method for inducing T cell reprogramming into NK-like cells, comprising the following steps: (1) culturing the T cells in a culture system to obtain activated T cells; (2) adding small molecule inducers twice to the activated T cells to obtain NK-like cells; wherein the culture system in step (1) contains 1-10 v / v % serum substitute and / or platelet lysate, and does not contain fetal bovine serum. By optimizing the culture process and precisely adding drugs twice, the small molecule accumulation toxicity caused by multiple drug additions is avoided, the damage to the structure and function of the mitochondrial membrane is reduced, the mitochondrial membrane potential is significantly improved, the energy metabolism capacity of the mitochondria is enhanced, sufficient energy support is provided for the long-term survival and function maintenance of the cITNK cells, and the physiological activity of the cells is ensured from the energy metabolism level.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

The invention discloses a system for monitoring the influence of atorvastatin on mitochondrial functions in real time, and the system comprises a biosensor module which is used for monitoring biomarkers related to the mitochondrial functions and glycometabolism in blood in real time; the micro-fluidic chip is used for rapidly separating and enriching cells or specific components in blood; the optical detection module monitors the active oxygen level of mitochondria in real time; the data processing and transmission module processes and analyzes the collected data in real time; the equipment terminal receives the processed data and displays the data on a user interface in real time; the analysis and early warning module analyzes the monitoring data in real time and provides early warning and personalized suggestions for diabetes mellitus; the database module is used for storing monitoring data and historical records; through a biosensor, optical detection, a micro-fluidic chip and the like, after a patient takes atorvastatin, indexes of blood sugar, insulin and the like in a blood sample, and mitochondrial functions and oxidative damage indexes of active oxygen level, mitochondrial membrane potential and the like are detected.

The application discloses a kind of mitochondrial fluorescent probe independent of mitochondrial membrane potential and its preparation method and application, the mitochondrial fluorescent probe independent of mitochondrial membrane potential provided by the application can target and image mitochondria when mitochondrial membrane potential decreases and disappears.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The application belongs to the technical field of cell biology, and provides an oocyte in vitro maturation culture medium additive and application thereof. The experimental results of the application show that coumarin 106 can improve the meiosis process blockage of oocytes, reduce the morphological proportion of abnormal spindle and the proportion of misaligned chromosomes, restore the level of acetylated tubulin, improve microtubule stability, improve the expression level of actin in the spindle of oocytes, improve the misdistribution and expression decrease of mitochondria in oocytes, improve the level of mitochondrial membrane potential, improve the fluorescence signal of cortical granules and specific cortical granule proteases in oocytes, improve the fertilization rate, reduce the level of reactive oxygen species and DNA damage in oocytes, and reduce the occurrence of early apoptosis in oocytes. The culture medium prepared by using coumarin 106 can be used for promoting oocyte in vitro maturation.

The invention discloses application of berberine in preparation of a medicine for treating non-small cell lung cancer, and belongs to the technical field of biological medicine. The invention provides an application of berberine in preparation of a medicine for inhibiting or treating EGFR (epidermal growth factor receptor) driven diseases, or an application of berberine combined with other medicines in preparation of a medicine for inhibiting or treating EGFR driven diseases. The diseases comprise non-small cell lung cancer driven by EGFR (epidermal growth factor receptor). It is found that in PC-9 cells, berberine induces ROS accumulation and starts a mitochondrial injury pathway, then mitochondrial membrane potential is reduced, GSDME is activated to form an active N-terminal fragment (GSDME-N), then pyroptosis is induced, NSCLC cell proliferation is inhibited, and berberine is expected to overcome or delay EGFR TKI drug resistance and improve clinical effects and survival prognosis.

This invention discloses the application of miR-182 in the preparation of drugs for combating neuronal hypoxia-induced damage and the drugs themselves, relating to the field of biomedical technology. The nucleotide sequence of miR-182 is shown in SEQ ID NO.1. This invention reveals for the first time the core role of miR-182 in combating neuronal hypoxia-induced damage. Experimental results show that miR-182 can effectively block hypoxia-induced neuronal mitochondrial dysfunction. Under extreme conditions of 1% oxygen concentration, miR-182 intervention can significantly maintain the stability of mitochondrial membrane potential, prevent the collapse of the core energy metabolism unit, and provide a critical time window for the repair of damaged neurons.

This invention relates to mitochondrial-enriched extracellular vesicles, their preparation methods, and applications, which can effectively solve the drug problem in spontaneous intracerebral hemorrhage. The technical solution involves using platelets as raw material, and obtaining platelet-derived extracellular vesicles carrying active mitochondria through activation induction, differential centrifugation and fractionation, membrane filtration and elution enrichment. This achieves efficient and stable loading of functional mitochondria, and the resulting PEV Mito has a complete structure and uniform particle size, which can effectively maintain mitochondrial membrane potential and biological activity. It can achieve efficient delivery and intracellular internalization to damaged neurons and restore mitochondrial function. The PEV Mito prepared by this invention has high delivery efficiency and excellent biocompatibility, and can be used to prepare drugs for the treatment of intracerebral hemorrhage and secondary neurological injury, with good prospects for clinical translation.

The invention provides a device and method for screening materials for improving mitochondrial functions, and the device comprises a nano-engineered mitochondrial delivery module, a biological resonance energy regulation and control module, a multi-parameter real-time monitoring and analysis module and a recipient cell layer, the nano-engineered mitochondria conveying module comprises a micro-fluidic chip for separating and suspending mitochondria, a pressure driving device for providing conveying power, and a porous membrane for bearing recipient cells. According to the invention, the nano-engineered mitochondrial delivery module, the biological resonance energy regulation and control module and the multi-parameter real-time monitoring and analysis module are integrated on the same platform, so that subtle changes of key indexes such as mitochondrial membrane potential, ATP synthesis efficiency and ROS level can be dynamically captured in real time; the limitation that only end point data can be obtained in a traditional method is avoided, so that the dynamic influence of the material on the mitochondrial function can be evaluated more accurately, and the accuracy and reliability of a screening result are improved.

The present application relates to a kind of compositions for regulating autophagy of eukaryotic cell, improving mitochondrial dysfunction and its preparation method and application.It includes the following weight parts of raw materials: 10-30 parts of broccoli powder, 10-30 parts of wheat germ microcapsule powder, 20-40 parts of raspberry extract, 20-40 parts of banana powder, 2-6 parts of leucine, 0.1-1 parts of pyrroloquinoline quinone disodium salt.The present application also provides the preparation method of broccoli powder, wheat germ microcapsule powder, raspberry extract and banana powder, and the use of the composition.The composition combines the efficacy of the above 6 ingredients, reasonable compatibility, safe and effective, various components activate mitochondria through regulating protein, PINK1 / Parkin-dependent pathway and PINK1 / Parkin-independent pathway;At the same time, by activating PGC-1 alpha signal pathway, promote mitochondrial DNA replication and new mitochondria generation;Stabilize mitochondrial membrane potential, improve ATP synthesis efficiency;Synergistically activate mitochondrial autophagy, improve mitochondrial dysfunction and then relieve aging.

The invention discloses a novel application of a compound beta-alanine (beta-alanine) in preparation of a medicine for improving oocyte quality and treating ovarian endometriosis (OEM) related infertility, and belongs to the technical field of biological medicines. An OEM animal model proves that beta-alanine can remarkably improve reproductive function disorder of model animals, specifically, follicular dysplasia caused by endometriosis is effectively relieved, the fertility is improved, and the litter size is increased; in the aspect of oocyte quality, the compound can promote normal discharge of a first polar body in an oocyte in-vitro maturation process, reduce cytoplasm fragmentation, recover spindle body form and microtubule arrangement, enhance mitochondrial membrane potential stability and maintain the integrity of an ultrastructure. The results show that beta-alanine can reverse oocyte quality reduction caused by ovarian endometriosis in multiple dimensions, has a definite treatment potential, and provides an important candidate molecule for developing a novel assisted reproduction intervention strategy for targeting oocyte health.

The present invention relates to a method for activating the mitochondrion, wherein mainly negative charges and reactive oxygen species are supplied to the mitochondrion from the outside via a negative charge and reactive oxygen species delivery unit to serve as material for the mitochondrial redox reaction. A calcium ion channel stimulation unit stimulates an in vivo calcium ion to transport the protein across the calcium on the inner mitochondrial membrane into a mitochondrial matrix space, such that the influx of calcium ions promotes mitochondrial depolarization and increases the activity of mitochondrial oxidative phosphorylation. This enhances mitochondrial activation and ATP production.

The application relates to a mitochondrial membrane potential detection probe technology, in particular to a dual-color fluorescence probe for self-referenced monitoring of mitochondrial membrane potential and application thereof.The probe comprises a compound CBTH or pharmaceutically acceptable salts, hydrates, solvates, optical isomers, racemates and the like of the compound CBTH.The chemical structural formula of the compound CBTH is shown as formula (I).The probe CBTH can be imaged simultaneously in dual colors, the fluorescence intensity does not disappear with the change of the cell state, and the change of the mitochondrial membrane potential can be monitored semi-quantitatively by calculating the colocalization coefficient.The probe has low toxicity, good biocompatibility, reduces the cumbersome operation of co-staining of two probes, and is expected to be widely applied in the research on diseases and physiological processes related to mitochondria.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and / or treating retinal ischemia hypoxic nerve injury diseases, and relates to the technical field of biological medicines. The invention proposes and verifies for the first time that salvianolic acid C can significantly promote the formation of stress particles in photoreceptor cells under retinal ischemia and hypoxia conditions, and drives the salvianolic acid C to be assembled into a stress particle-mitochondrial micro-region in a mitochondrial adjacent region. The microcell is enriched in DDX3X, LARP1 and other key RNA binding proteins and multiple mitochondrial related proteins to cooperatively maintain mitochondrial membrane potential, inhibit mPTP opening and reduce ROS generation, so that an endogenous apoptosis pathway is inhibited, and the neuroprotective effect on a photoreceptor is achieved. On the basis, the salvianolic acid C is used for preparing the medicine for preventing and / or treating the retinal ischemia hypoxia nerve injury disease, can be used as a nerve protection supplement for existing anti-VEGF treatment, and has innovativeness and application value.

The application belongs to the technical field of target drugs, and particularly relates to application of CASZ1b protein; the amino acid sequence of the CASZ1b protein is shown as SEQ ID NO. 1, and the application of the CASZ1b protein in preparation of a drug for treating diseases mediated by mitochondrial function damage; the drug can activate expression of mitochondrial autophagy proteins Beclin1 and P62, improve a mitochondrial membrane potential, inhibit ROS production, and repair mitochondrial function damage.